Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cevostamab + Pomalidomide + Dexamethasone in Multiple Myeloma Post-BCMA CAR T
NCT07825064Phase 2Recruiting
- Sponsor
- Roche
- Start
- Oct 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cevostamab in multiple myeloma (MM), sponsored by Roche. Primary endpoint: Overall Response Rate up to 3 years. Started Oct 2026; status: recruiting.
02
Drugs
cevostamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07825064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07825064.